Table 2

Cox regression analyses of survival among surrogate molecular subtypes by immunohistochemistry in primary DCIS (n=458), by follow-up period
Follow-up period
> 3 months – 10 years > 10 years
Type of event Unadjusted HR (95% CI) Adjusted* HR (95% CI) Unadjusted HR (95% CI) Adjusted* HR (95% CI)
Local recurrence (in situ or invasive) No. of events: 84 No. of events: 17
Luminial A 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Luminal B/HER2- 1.39 (0.64-3.01) 1.61 (0.73-3.54) no events -
Luminal B/HER2+ 1.31 (0.72-2.40) 1.63 (0.84-3.17) 0.78 (0.21-2.89) 1.01 (0.22-4.62)
HER2+/ER- 1.21 (0.62-2.34) 1.77 (0.85-3.68) 0.27 (0.03-2.14) 0.58 (0.06-5.89)
Triple negative 1.37 (0.57-3.28) 1.38 (0.56-3.38) 0.94 (0.12-7.44) 0.78 (0.09-7.22)
Unclassified 0.73 (0.36-1.49) 0.77 (0.38-1.58) 0.95 (0.25-3.60) 1.19 (0.29-4.78)
Invasive or general recurrence No. of events: 47 No. of events: 19
Luminial A 1.0 1.0 1.0 1.0
Luminal B/HER2- 2.02 (0.80-5.13) 2.51 (0.97-6.49) no events -
Luminal B/HER2+ 1.49 (0.68-3.25) 1.97 (0.83-4.67) 0.78 (0.25-2.44) 0.72 (0.21-2.56)
HER2+/ER- 0.71 (0.24-2.12) 0.98 (0.31-3.17) no events -
Triple negative 2.24 (0.83-6.06) 1.99 (0.70-5.63) 0.82 (0.11-6.35) 0.63 (0.07-5.48)
Unclassified 0.70 (0.26-1.90) 0.84 (0.31-2.33) 0.54 (0.12-2.42) 0.53 (0.12-2.42)
All events No. of events: 112 No. of events: 28
Luminial A 1.0 1.0 1.0 1.0
Luminal B/HER2- 1.24 (0.62-2.46) 1.47 (0.73-2.94) no events -
Luminal B/HER2+ 1.20 (0.71-2.01) 1.53 (0.87-2.71) 0.40 (0.12-1.37) 0.39 (0.11-1.45)
HER2+/ER- 0.92 (0.49-1.70) 1.28 (0.65-2.52) 0.17 (0.02-1.25) 0.20 (0.03-1.58)
Triple negative 1.30 (0.61-2.75) 1.37 (0.64-2.98) 2.95 (1.07-8.16) 3.21 (1.05-9.83)
Unclassified 0.78 (0.43-1.39) 0.82 (0.45-1.48) 0.85 (0.28-2.58) 1.02 (0.33-3.21)

*Adjusted for age, mode of detection, size, grade, surgery and radiotherapy.

Zhou et al.

Zhou et al. BMC Cancer 2013 13:512   doi:10.1186/1471-2407-13-512

Open Data